Penumbra Q3 rev $213.7M (+12.4%); cuts FY22 guide to $840-845M on Flash delay, FX headwind

Penumbra Inc

2022-Q3 EPS reported -$0.16 revenue$625,917,000

Revenue $213.7M, +12.4% YoY (+15.1% constant currency); vascular +17%, neuro +6.7%.
GAAP operating income $5.4M vs $8.8M prior year; non-GAAP op income $7.8M.
FY2022 revenue guidance reduced to $840-845M; cites Lightning Flash launch delay to Q1 2023 and $4-6M FX headwind.
Expects to reach $1B revenue in 2023.
Gross margin 63.3% vs 63.1% prior year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Penumbra Inc updated its 2022 guidance (lowered).

Period: 2022
Guidance: lowered
Result: guidance update

Exact text from the filing

The Company now expects 2022 total revenue to be in the range of $840 million to $845 million, which reflects growth of 12-13% on a reported basis and 15-16% in constant currency compared to 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Penumbra Inc reported the third quarter ended September 30, 2022 results: revenue $213.7 million. Guidance lowered.

Period: the third quarter ended September 30, 2022
Revenue: $213.7 million
Guidance: lowered
Result: reported results

Exact text from the filing

Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2022. • Revenue of $213.7 million in the third quarter of 2022, an increase of 12.4%, or 15.1% in constant currency 1 , compared to the third quarter of 2021. Third Quarter 2022 Financial Results Total revenue

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Penumbra Inc filing history →

Source: SEC EDGAR

accession 0001321732-22-000103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.